INTRODUCTION
Reovirus is a double stranded RNA virus with oncolytic activity in a variety of cancer cell types [1] . Although reovirus has been demonstrated to replicate independently of the Ras-EGFR pathway in certain cells [2] , direct oncolysis can occur as a result of defective anti-viral PKR signalling in many tumor cells, leading to efficient viral replication and preferential tumor cell lysis. We, and others, have also shown that the anti-tumor efficacy of reovirus depends upon a potent anti-tumor immune response through activating dendritic cells (DCs) to stimulate both NK cell and T cell mediated cytotoxicity [3] [4] [5] [6] [7] [8] . Following on from these pre-clinical studies, safety of reovirus serotype 3 Dearing strain (Oncolytics, Reolysin) alone, or in combination with other therapies, has been demonstrated in several phase I/II clinical trials [9] [10] [11] [12] [13] [14] [15] [16] During normal cellular immune homeostasis, several immune checkpoint ligand-receptor interactions act as negative regulators of T cell responses to regulate autoimmunity and prevent damage to healthy tissues [17] . Programmed cell death-1 (PD-1) is a checkpoint receptor expressed on T, B cells, and monocytes [18, 19] , binding of which to its ligands PD-L1, PD-L2 inhibits T cell activation [20, 21] . In this way, expanding T cell responses to, for example, viral infections or tumor development, are restricted and dampened. In this respect, it is now clear that expression of molecules such as PD-L1 is one of the many mechanisms which tumors employ to inhibit developing anti-tumor T cell responses [22] [23] [24] and evade immune surveillance [25] . As a result, antibodies blocking the interaction of immune checkpoint molecules expressed on the surface of tumor cells with their ligands on immune cells, have been shown to ameliorate such tumor-induced immune suppression and enhance anti-tumor responses [26, 27] . Clinical trials have now shown the efficacy of anti-checkpoint inhibitor antibodies for the treatment of cancer patients [28] [29] [30] and FDA approval has recently been granted for their clinical use.
A c c e p t e d m a n u s c r i p t
Since oncolytic viruses activate anti-tumor immune effector cells, either innate and/or adaptive antitumor therapy may actually benefit from those immune responses which contribute to tumor clearance [7, [37] [38] [39] , in which case immune checkpoint inhibition may add to, or synergise with, direct oncolytic virotherapy in clearing tumor cells. Finally, any differential effects of immune checkpoint inhibitors on both innate, and adaptive, immune effectors, to both virus and tumor, will also impact on overall treatment efficacy. Thus, although de-suppression of local acting, innate immune responses to virus infection may act to restrict viral oncolysis, it may, conversely, increase local immune-mediated tumor clearance. Similarly, immune checkpoint inhibition of slower developing, adaptive antitumor T cell responses would be expected to contribute to improved overall therapy, whilst preventing the suppression of antiviral T cell responses may lead to decreased efficacy of repeated treatments. Therefore, the overall therapeutic effects of immune checkpoint inhibitor therapy, in combination with oncolytic viroimmunotherapy are likely to be dependent upon multiple factors including the nature of the virus, the checkpoint inhibitor, the tumor type and pragmatic issues such as the relative timing of administration of the agents.
Therefore, in the current study, we investigated whether it would be possible to combine systemic checkpoint inhibitor therapy with local viroimmunotherapy using oncolytic reovirus in A c c e p t e d m a n u s c r i p t our pre-clinical model of subcutaneous (s.c.) B16 melanoma. We show here that combining intravenous (i.v.) anti-PD-1 antibody with intra-tumoral (i.t.) reovirus, significantly enhanced survival compared to either therapy alone. Successful combination therapy was associated with an enhanced ability of natural killer (NK) cells to recognize, and kill, reovirus-infected target tumor cells, an anti PD-1 antibody-mediated reduction in regulatory T cell (T reg ) activity in reovirus-treated mice, and an increased adaptive CD8+ antitumor T cell response. Our data show that combination with checkpoint inhibition represents a readily translatable next step in the clinical development of reovirus viroimmunotherapy.
RESULTS

PD-1 blockade with i.t. reovirus prolongs survival.
We used a regimen of treatment of s.c. B16
tumors in C57Bl/6 immune competent mice with i.t. reovirus [5] such that virus delayed tumor growth but had no significant effect on survival compared to PBS-treated mice (Fig.1 ). In this model, systemic treatment with anti-PD-1 antibody also gave no survival benefit (Fig.1) . In contrast, when anti-PD-1 antibody was administered starting 7 days after the first i.t. virus treatment, combining both treatments significantly prolonged survival of mice (p< 0.001 compared to i.t. reovirus), and cured ~40% of mice. Cured mice were tumor free for >100 days.
PD-1 blockade and reovirus together augments the IFN-γ response against melanoma tumorassociated
antigens. An IFN-γ memory recall response to B16 tumor cell lysates was detected from pooled splenocytes and lymph node (splenocytes/LN) cells of mice treated with i.t.
reovirus, but not from mice treated with i.t. PBS (p=0.035) (Fig.2a) , confirming our previous reports that oncolytic reovirus effectively primes antitumor T cell responses [4, 8] . Consistent with the increased therapy associated with combination with anti-PD-1 treatment (Fig.1) , splenocytes/LN from mice treated with the combination of reovirus and anti-PD-1 generated significantly higher levels of IFN-γ in response to B16 tumor lysates compared to reovirus alone (p=0.017) (Fig.2a) . <20ng/ml of IFN-γ were secreted in response to lysates of the lysates, addition of anti-PD-1 treatment to i.t. reovirus significantly enhanced the magnitude of the anti-melanoma responses (Fig.2b) . These data show that addition of PD-1 checkpoint inhibition to reovirus therapy augments the in vivo IFN-γ response against melanoma tumorassociated antigens.
PD-1 blockade augments reovirus-induced NK cell activation and killing. We have previously
shown that both tumor [4, [6] [7] [8] , and immune [3] , cell infection with reovirus elicits NK cell mediated innate immune responses. Therefore, we investigated the impact of anti-PD-1 treatment on NK cell recognition of reovirus-infected tumor cells. Neither B16 tumor cells, nor cultures enriched for purified splenic NK cells, alone produced high levels of tumor necrosis factor alpha (TNF-α). However, co-culture of both together led to a significant increase in TNF-α production (p<0.0001), which was significantly further enhanced when the B16 cells were pre-infected with reovirus (p<0.0001, 2-way ANOVA) (Fig.3a) . Addition of anti-PD-1 antibody significantly increased TNF-α production by NK-enriched cultures in the presence of reovirus pre-infection of B16 targets compared to co-cultures treated with an isotype control (p<0.0001), but did not alter NK recognition of uninfected B16 targets (Fig.3a) . In vitro PD-L1 blockade had a much smaller, although still significant, effect on enhancing NK recognition of reovirusinfected B16 cells (p<0.0001) (Fig.3a) .
Although co-culture of NK-enriched cultures with reovirus-infected tumor cells did not significantly reduce reovirus titers produced by the B16 cells (Fig.3b) , addition of anti-PD-1 antibody to these co-cultures resulted in a significant decrease in reovirus titers (p=0.037)
A c c e p t e d m a n u s c r i p t (Fig.3b) , presumably reflecting the decreased tumor cell numbers available for reovirus replication (Fig.3c) . Neither anti-PD-L1, nor isotype control IgG, decreased reovirus titers compared to co-cultures with NK cells alone (Fig.3b) . The addition of anti-PD-1, anti-PD-L1 or isotype control antibodies to uninfected B16-NK co-cultures had no effect on tumor cell survival (Fig.3c) . Consistent with additional virus-mediated killing of B16 cells, addition of reovirus to B16/NK co-cultures reduced viable cell numbers (Fig.3c) . However, the addition of anti-PD-1
antibody to reovirus-infected B16 /NK cell co-cultures significantly augmented NK cellmediated tumor killing compared to the addition of no antibody (p=0.012), a control IgG or anti-PD-L1 antibody (Fig.3c ). Although PD-1 expression could be detected at low levels on resting CD4 cells, minimal levels of PD-1 were detectable on the resting CD8 T cells and NK cells used in these experiments ( Fig.3D-F) . Therefore, the anti-PD-1-augmented NK activation of tumor cell killing by reovirus infection observed in these NK-enriched populations in vitro 
Reovirus in combination with NK cells affects the levels of PD-L1 on tumors.
The B16 cells used in this study expressed high levels of PD-L1 (Fig.4a ) but these were not significantly changed upon infection by reovirus at the indicated MOI (Fig.4a) . Similarly, co-culture of B16 cells with NK cells in vitro did not alter the high levels of PD-L1 expressed by the tumor cells (Fig.4b) . Pre-infection of the tumor cells with reovirus, followed by co-culture with NK cells, led to a small increase in PD-L1 levels on the B16 cells (Fig.4b) . PD-L1 levels on NK cells were not altered by reovirus infection of B16 cells prior to co-culture (Fig.4c ). Taken together, these compared to non-depleted mice (Fig.6 ). However, depletion of CD4+ T cells had no significant effect on antitumor therapy (Fig.6 ).
DISCUSSION
We show here, for the first time to our knowledge, that reovirus oncolytic viroimmunotherapy can be successfully combined with immune checkpoint inhibitor therapy. Our data complement previous reports in which other oncolytic viruses have been used in tandem with immune checkpoint inhibitors [33] [34] [35] . Cumulatively, these data sets confirm that oncolytic A c c e p t e d m a n u s c r i p t virotherapy can be regarded as a form of immunotherapy and that strategies aimed at enhancing the immune based component of this approach are likely to enhance its therapeutic efficacy [5] [6] [7] .
Consistent with our previous studies on reovirus oncolysis in the B16 model [4, [6] [7] [8] 40 ] i.t.
injection of established tumors primed tumor-specific Th1 T cell responses against both tumor cells (Fig.2a) , and against defined melanoma-associated antigens (Fig.2b) . These results indicated that both direct oncolysis, as well as the immune based activation that accompanies it [4, 6, 8, 40] , provides sufficient immune activation to break tolerance to self -antigens expressed by the tumor (Fig.2b) . Therefore, we hypothesized that the immune stimulating, T cell priming activity associated with direct oncolysis by reovirus could be effectively combined with immune checkpoint inhibition. In this way, the weak antitumor T cell responses generated by the immunostimulatory activity of the virus would be enhanced by blockade of negative regulatory signals to the activated self-responsive T cells. Consistent with this hypothesis, direct i.t. injection of reovirus, followed 7 days later by multiple systemic administrations of anti-PD-1 antibody, significantly improved on the therapy associated with either virus, or anti-PD-1 antibody, alone (Fig.1) .
We initially showed a significant increase in the IFN-γ response to B16 tumor in splenocytes/lymph node cells from mice treated with reovirus and anti-PD-1 compared to reovirus alone (Fig.2) . To dissect the cellular basis of this response in more detail, we proceeded to show that the response is mediated by NK cells (Figs.3&6) , Treg ( (Fig.3a) . In the presence of anti-PD-1 antibody, NK cell activation by reovirus infection was significantly enhanced as evidenced by TNF-α secretion (Fig.3a) and target cell killing (Fig.3c) . Interestingly, at least in the context of this in vitro assay, anti-PD-1 antibody decreased the viral titers associated with NK/B16-reovirus infection (Fig.3b) , suggesting that the increased immune based killing associated with NK/anti-PD-1 recognition of reovirusinfected tumor cells may be more important than direct oncolysis effects. Taken together with the in vivo confirmation of a strict dependence upon NK cells for reovirus/anti-PD-1 therapy (Fig.6 ), overall our data show that NK activation by, and killing of, B16 tumor cells is significantly enhanced by blockade of PD-1. However, we were unable to detect PD-1 expression on NK cells from splenocytes/lymph node cells from C57Bl/6 mice ( Fig.3 ), although these cells had high levels of PD-L1 (Fig.4) . Therefore, it seems probable that the NKdependence of the in vitro (Fig.3 ) and in vivo ( Therefore, taken together, the in vivo mechanisms by which i.t. reovirus leads to anti-PD-1 augmented therapy are likely to be pleiotropic, involving both innate and adaptive immune effector mechanisms (Figs. 2,3,5&6 ).
Reovirus infection alone did not significantly alter the levels of PD-L1 on B16 tumor cells (Fig.4a ), but addition of NK cells to reovirus infected B16 cells increased PD-L1 on the tumor cells (Fig 4b) . Therefore, our in vitro data suggest that the therapeutic effects of i. In vitro cultures of splenocytes/LN cells from treated mice showed that the anti-PD-1-mediated enhancement of T cell responses against melanoma-associated antigens (Fig.2) was almost entirely dependent upon CD8+ T cells (Fig.5a ), a result that was also confirmed in vivo (Fig.6 ).
As predicted, in vivo blockade of PD-1 also significantly enhanced the Th1 anti-reovirus T cell A c c e p t e d m a n u s c r i p t response (Fig.5b). However, Fig.5c shows that additional immune effectors contributed to the virus specific Th1 response, since in vitro depletion of CD8+ T cells did not completely abolish anti-reovirus IFN-γ secretion. It seems likely that NK cell mediated IFN-γ secretion may contribute, in part at least, to the anti-reovirus responses seen in these splenocyte/LN cultures given the role of NK cells shown in Fig.3 .
Just as depletion of CD8+ T cells abolished the antitumor Th1 response induced by i.t. reovirus alone (Fig.5a ), so in vitro depletion of T reg dramatically increased it (Fig.5a ). These in vitro data correlate closely with our previous in vivo data, which showed that i.t. reovirus is associated with induction of a strong T reg response, which can be suppressed by antibodymediated depletion of T reg , or by treatment with cyclophosphamide [5] . Interestingly, the in vitro In contrast to the results with the antitumor Th1 response, the anti-reovirus Th1 response was only moderately increased by in vitro depletion of T reg (Fig.5c) . Moreover, the anti-PD-1-mediated enhancement of the antivirus Th1 response (Fig.5b) was further enhanced by in vitro depletion of T reg (Fig.5c ). These data suggest that blockade of PD-1 does not completely mimic T reg depletion/abrogation in the context of the antivirus (Fig.5c) , as opposed to the antitumor (Fig.5a ), response. Taken together, our data show that PD-1 blockade enhanced both tumor-specific, and viral-specific, immune responses, but may be acting through different immune effectors including CD8+ T cells, NK cells and T reg .
Overall, our in vivo data show that tumor clearance by the combination of local oncolysis and systemic immune checkpoint inhibition absolutely depended upon immune effectors (NK, Fig.6 ) and that the regimen tested here led to significant synergy between the two therapies. However, the use of immune checkpoint inhibitors in the context of oncolytic virotherapy poses several possibly conflicting questions regarding its predicted therapeutic efficacy. Thus, whilst de-repressing an antitumor, adaptive T cell immune response is likely to be beneficial to tumor clearance, de-suppressing antiviral responses (innate or adaptive), which normally act to restrict viral spread, may limit further replication which could be detrimental to the efficacy of the directly oncolytic component of the virotherapy [31, 36] .
A c c e p t e d m a n u s c r i p t CD8+ T cells,
Conversely, antitumor therapy may benefit from augmenting immune responses, even against the virus, which contribute to tumor clearance [7, 32, 37, 39] . Therefore, it is clear that the differential effects of immune checkpoint inhibitors on both innate, and adaptive, immune effectors, to both virus and tumor, need to be understood to allow for optimal utilization of these agents in combination with oncolytic virotherapy. Our data here clearly show that the effectors and mechanisms of the antitumor, and antiviral, Th1 responses both share some components but also differ in some significant respects. Therefore, it will be important to optimize several factors, which may play both complementary, and/or opposing, roles in the success of this combination therapy. In particular, the relative timing of virus and checkpoint inhibition may be crucial. Here, we started anti-PD-1 blockade 7 days after the first virus administration. The rationale of this was to minimize augmenting the anti viral response whilst virus injections were still being performed, thereby maximizing the ability of the virus to spread within the tumor. In the regimen of Fig.1 , the last reovirus injection was only 2 days before the first systemic treatment with anti-PD-1. Therefore, we believe that appreciable levels of intratumoral reovirus would likely still be present to activate NK cell mediated tumor killing, through mechanisms which would be augmented by anti-PD-1 as shown in Fig.3 . In addition, this timing was designed to prevent T cell inactivation as the antitumor immune response was developing (5-7 days after the initial T cell priming activity of i.t. virus injection (Fig.2b) .
A c c e p t e d m a n u s c r i p t
Therefore, the overall therapeutic effects of immune checkpoint inhibitor therapy, in combination with oncolytic viroimmunotherapy, are likely to be dependent upon multiple factors including the nature of the virus, the particular checkpoint inhibitor, the tumor type and pragmatic issues such as the relative timing of administration of the agents.
In summary, we show here that oncolytic reovirus therapy can be effectively combined with immune checkpoint inhibitor therapy. Blockade of PD-1 significantly enhanced the CD8+ T cell 
